Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Hire More Ex-Company Employees: Dr Aoki
January 21, 2008
- Takeda, Daiichi Sankyo Files NDAs for Their Future Blockbusters in the US
January 21, 2008
- REGULATORY NEWS IN BRIEF
January 21, 2008
- Meiji Seika Aims at \10 Bil. Sales with Generics
January 21, 2008
- NEW PRODUCTS／Dinagest Tablet for Endometriosis: Mochida
January 21, 2008
- Taisho Licenses TS-032 to Pfizer
January 21, 2008
- Tacere to Codevelop RNAi Hepatitis C Drug with Pfizer
January 21, 2008
- Mochida Licenses Analgesic to Wyeth
January 21, 2008
- Toyama Starts PII Study for T-705
January 21, 2008
- Novartis to Close Its Tsukuba Research Institute
January 21, 2008
- REGULATORY NEWS IN BRIEF
January 14, 2008
- Complete Lifting of Ban on Kongyo Shinryo Not Recommended by Council
January 14, 2008
- Non-Tamiflu Users Show Higher Incidence of Abnormal Behavior: Study Team Report
January 14, 2008
- ON THE MOVE／J&J Appoints D. W. Powell President
January 14, 2008
- Abnormal Behavior Reported in 38% of Patients Not Taking Tamiflu
January 14, 2008
- R&D NEWS IN BRIEF
January 14, 2008
- Nexavar, Licomodulin, Zevalin to Be Officially Approved Soon
January 14, 2008
- Korosho's General Account Budget to Total \22,117.9 Bil.
January 14, 2008
- Korosho to Promote the Use of Generics by Welfare Recipients
January 14, 2008
- Rules to Be Revised to Oblige Pharmacists to Dispense Generics: Mr Urushibata
January 14, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…